{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:27:02Z","timestamp":1791084422432,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270234"],"award-info":[{"award-number":["82270234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130003"],"award-info":[{"award-number":["82130003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341206"],"award-info":[{"award-number":["82341206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370223"],"award-info":[{"award-number":["82370223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2024SSYS0025"],"award-info":[{"award-number":["2024SSYS0025"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2024C03156"],"award-info":[{"award-number":["2024C03156"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2024SSYS0023"],"award-info":[{"award-number":["2024SSYS0023"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcyt.2026.102074","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:43:39Z","timestamp":1769701419000},"page":"102074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"28","author":[{"given":"Shan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102074_bib0001","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1182\/blood.2020007311","article-title":"Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia","volume":"137","author":"Ribera","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102074_bib0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-016-0519-8","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia in adults","volume":"18","author":"Ronson","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jcyt.2026.102074_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102377","article-title":"Donor-derived anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial","volume":"67","author":"Luo","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcyt.2026.102074_bib0004","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/bjh.19463","article-title":"Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia","volume":"204","author":"Kinsella","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0005","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bbmt.2013.04.014","article-title":"Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Poon","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102074_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0007","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102074_bib0008","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102074_bib0009","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102074_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102074_bib0011","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102074_bib0012","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0013","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102074_bib0014","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-024-01626-6","article-title":"Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0015","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102074_bib0016","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102074_bib0017","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41586-025-08657-0","article-title":"HIV immune evasin Nef enhances allogeneic CAR T cell potency","volume":"640","author":"Perica","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102074_bib0018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","article-title":"Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy","volume":"22","author":"An","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcyt.2026.102074_bib0019","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41375-024-02251-5","article-title":"Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"38","author":"Lu","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102074_bib0020","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.25630","article-title":"Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome","volume":"94","author":"Tu","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0021","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102074_bib0022","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102074_bib0023","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group Report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102074_bib0024","series-title":"NCCN Clinical Practice Guidelines in Oncology: acute lymphoblastic leukemia, version 1","author":"Alvarnas","year":"2016"},{"key":"10.1016\/j.jcyt.2026.102074_bib0025","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.23.00088","article-title":"Outcome for children and young adults with T-cell ALL and induction failure in contemporary trials","volume":"41","author":"Raetz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0026","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/leu.2012.231","article-title":"Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"27","author":"Denys","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102074_bib0027","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0028","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1038\/bcj.2016.51","article-title":"Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome","volume":"6","author":"Cher","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102074_bib0029","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102074_bib0030","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102074_bib0031","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102074_bib0032","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","article-title":"Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant","volume":"35","author":"Zhang","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102074_bib0033","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102074_bib0034","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102074_bib0035","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102074_bib0036","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.15973","article-title":"Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"186","author":"Nagler","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0037","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102074_bib0038","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0039","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102074_bib0040","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3389\/fimmu.2019.01625","article-title":"Computational analysis of HLA-presentation of non-synonymous recipient mismatches indicates effect on the risk of chronic graft-vs.-host disease after allogeneic HSCT","volume":"10","author":"Ritari","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102074_bib0041","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-015-0216-3","article-title":"Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT","volume":"8","author":"Zhang","year":"2015","journal-title":"J Hematol Oncol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:18:37Z","timestamp":1782199117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1465324926000307"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102074","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102074"}}